

## **(Preliminary!) Annual Report**

### **Working Group on Cardiovascular Pharmacology and Drug Therapy**

#### **Nucleus:**

Chairman: Faiez Zannad, Nancy, FR  
Vice-chairman: Luis Ruilope, Madrid, SP  
Past chairman: Dan Atar, Oslo, NO  
Treasurer: Keld Kjeldsen, Kobenhavn, DK  
Secretary: Kurt Stoschitzky, Graz, AT  
Web editor: Finn Gustafsson, Kobenhavn, DK  
Honorary Senior Advisor: Ferenc Follath, Zürich, CH  
Nucleus Members: Maria Angeles Alonso Garcia, Madrid, SP  
Wiek van Gilst, Groningen, NL  
Stefan Agewall, Stockholm, SE  
Franco Naccarella, Bologna, IT

#### **VOTES:**

*Elections during 2008:*

*3 nucleus members have resigned from the nucleus.*

*Online elections have been organised prior to the ESC congress in Munich, with the help of the ESC Office for WGs.*

## **Activities**

### **WG Annual Meeting = Endorsed Meeting:**

#### **▪ Meeting 1:**

Name: Cardiovascular Clinical Trialists Forum  
Chair / organisation committee: Faiez Zannad  
(Co-organiser: Dan Atar)  
N° of participants: 800  
N° of exhibitors: 20

### **Education programme:**

#### **Training 1:**

Name: Educational Autumn Meeting on  
Advances in Cardiovascular Drug Therapy  
"Treatment of hyperlipidaemia and diabetes:  
State of the art 2007"  
Chair / organisation committee: Kurt Stoschitzky  
N° of participants: 60  
N° of exhibitors: 4

## **Publications / Guidelines / Scientific Papers**

### ***Submitted by the WG (not by individuals)***

*Please specify Topics & Authors (specify if ordinary member or nucleus members)*

- **Is your WG officially affiliated to a journal? YES**  
Editors-in-Chief: Faiez Zannad and Pascal Bousquet  
Title: Fundamental and Clinical Pharmacology  
Contribution: Journal affiliated to our Working Group  
(The Editor [Faiez Zannad] is Chairman of our Working Group)
  
- **Position Papers / Consensus Documents:**  
European Medicines Agency Guideline on the Evaluation of Medicinal Products for Cardiovascular Disease Prevention
  
- **Participation to guidelines writing / reviewing:**
  - WG represented in the writing committee for the 2007 CV-Joint Prevention Guidelines (Dan Atar)
  - WG represented in the writing committee for the 2008 HF-guideline (Dan Atar)
  - WG represented in position paper "Bleeding complications in ACS" to be published in 2009 (Dan Atar)

## **Accepted Proposals for pre-arranged sessions at the ESC 2008 main congress and/or ESC Sub-specialty meetings**

### **Sessions at the ESC Congress 2008 in Munich (DE)**

This year, 4 accepted sessions were proposed by the Working Group:

#### **The odyssey from drug discovery to clinical practice.**

**Chairpersons: M L Simoons (Rotterdam, NL), E Braunwald (Boston, US)**

- When basic science is lost in translation. T F Lüscher (Zürich, CH)
- The dilemma implementing trial evidence into clinical practice. T R Pedersen (Oslo, NO)
- We treat individuals, not populations. D Atar (Oslo, NO)
- Current clinical trials are not addressing the real issues. V Fuster (New York, US)

#### **The value of surrogate end points in clinical trials**

**Chairpersons: F Follath (Zurich, CH), W H van Gilst (Groningen, NL)**

- Intima media thickness. S Agewall (Oslo, NO)
- Atherosclerotic load imaging. R Corti (Zürich, CH)
- Biomarkers. A Maisel (San Diego, US)
- How useful are surrogates in clinical practice? S J Pocock (London, GB)

#### **New frontiers in hypertension**

**Chairpersons: K Stoschitzky (Graz, AT), S Taddei (Pisa, IT)**

- Vitamin D and hypertension: more light, please. M Hermann (Zürich, CH)
- Renin-angiotensin vaccination. J Nussberger (Lausanne, CH)
- Renin - back into the arena. A Danser (Rotterdam, NL)
- Long-term prevention of arterial hypertension: a dream yet to become true. T M MacDonald (Dundee, GB)

#### **The safety catch: cardiovascular safety of non-cardiovascular drugs**

**Chairpersons: F Zannad (D.-Les-Toul Cedex, FR), FT Ruschitzka (Zurich, CH)**

- Antidiabetic drugs. J G F Cleland (Kingston upon Hull, GB)
- Erythropoietin stimulating agents. H Krum (Melbourne, AU)
- Antiangiogenic and antiinflammatory drugs. F T Ruschitzka (Zürich, CH)
- Dopamine agonists and valvular heart disease. JS Borer (New York, US)

**Future projects:**

**Educational Autumn Meeting**, Wien, AT, November 2008

**Scandinavian Arrhythmia Spring Meeting**, Kobenhavn, DK, June 2009

**Cardiovascular Clinical Trialists Forum**, Cannes, FR, September 2009

**Finances:**

Balance sheet (September 2008): +EUR 3569,-

Yours sincerely,

Faiez Zannad (Chairman)  
Kurt Stoschitzky (Secretary)

From: Dan Atar [mailto:dan.atar@online.no]  
Sent: 19. november 2008 16:29  
To: 'Kurt Stoschitzky'  
Cc: Faiez ZANNAD; 'ruilope@ad-hocbox.com'  
Subject: RE: Antw: RE: Antw: RE: Antw: WG Pharmacology Annual Report2007/08

very nice, thanks Kurt

a few rectifications:

4. regarding the Vote: very important that you fill in what Celine instructed you to,  
she gave you a link with all details. Please insert here  
(if you are in doubt, please ask her directly)

please resend after rectification

thanks

Dan